REGN Q1 2018 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+14.6% YoY

Gross Profit

$1.4B90.0% margin

Operating Income

$567M37.5% margin

Net Income

$478M31.6% margin

EPS (Diluted)

$4.16

QoQ Revenue Growth

-4.5%

Cash Flow

Operating Cash Flow

$619M

Free Cash Flow

$539M

Stock-Based Comp.

$82M

Balance Sheet

Total Assets

$9.4B

Total Liabilities

$2.8B

Stockholders' Equity

$6.6B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.3B	+14.6%
Gross Profit	$1.4B	$1.2B	+13.7%
Operating Income	$567M	$431M	+31.7%
Net Income	$478M	$249M	+92.0%

Revenue Segments

Immuno-oncology Agreement

$1.7B95%

Antibody Collaboration

$88M5%